| Quarterly Financials | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
Revenue  | 24 | 31 | 36 | 36 | 25 | 28 | 31 | 33 | 22 | 28 | 33 | 34 | 23 | 34 | 34 | 36 | 39 | 42 | 44 | 47 | 48 | 44 | 45 | 45 | 35 | 44 |
| Expenses | 20 | 26 | 30 | 30 | 21 | 24 | 25 | 28 | 17 | 22 | 26 | 26 | 18 | 27 | 28 | 30 | 32 | 35 | 39 | 42 | 42 | 40 | 39 | 38 | 31 | 38 |
| EBITDA | 4 | 5 | 6 | 6 | 4 | 4 | 6 | 5 | 5 | 6 | 7 | 7 | 5 | 7 | 6 | 7 | 7 | 7 | 5 | 6 | 6 | 4 | 6 | 7 | 4 | 5 |
| Operating Profit % | 18 % | 16 % | 16 % | 15 % | 13 % | 15 % | 18 % | 16 % | 20 % | 22 % | 19 % | 19 % | 22 % | 17 % | 17 % | 17 % | 17 % | 17 % | 11 % | 11 % | 12 % | 8 % | 12 % | 15 % | -5 % | 11 % |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 1 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Profit Before Tax | 4 | 4 | 5 | 5 | 3 | 3 | 5 | 4 | 4 | 5 | 5 | 5 | 3 | 4 | 4 | 4 | 4 | 5 | 3 | 3 | 3 | 2 | 2 | 4 | 3 | 2 |
| Tax | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Profit | 2 | 3 | 4 | 4 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 4 | 4 | 4 | 4 | 4 | 2 | 2 | 2 | 1 | 1 | 3 | 2 | 2 |
| EPS in ₹ | 2.06 | 2.75 | 3.18 | 3.05 | 2.05 | 1.84 | 2.64 | 2.47 | 2.99 | 3.40 | 3.46 | 3.09 | 2.25 | 2.94 | 2.85 | 2.98 | 3.03 | 3.12 | 1.17 | 1.60 | 1.61 | 0.63 | 0.71 | 2.30 | 1.47 | 1.18 |
Medicamen Biotech
Medicamen Biotech
303.55
-21.50
(-6.61%)
There are 2 new updates from the company19 hours ago
View
Market Cap
411.70 Cr
EPS
5.60
PE Ratio
43.46
Dividend Yield
0.31 %
Industry
Healthcare52 Week High
630.00
52 Week Low
322.00
PB Ratio
1.60
Debt to Equity
0.15
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Company News
View All News
Medicameq Ltd approved its unaudited financial results for the quarter ended June 30, 2025. The board appointed Mr. Ashwani Kumar Sharma as Executive Director for five years, changing his role from Non-Executive Director. Two new Non-Executive Independent Directors were also appointed: Mr. Sham Goel, a Chartered Accountant with over 30 years of finance experience, and Mr. Shaival Saurabh, who has over 30 years of branding and advertising experience. The company's 32nd AGM is scheduled for September 26, 2025, and the board proposed a final dividend of 10% or Re. 1 per equity share for FY 2024-25. The auditors provided unmodified opinions on the quarterly results.
Medicamen Biotech Receives First ANDA Approval from USFDAJun 03, 2025
Medicamen Biotech has received its first Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for Bortezomib for injection. This approval is described as a significant milestone for the company.
Medicamen Biotech Approves Share and Warrant AllotmentApr 24, 2025
Medicamen Biotech has approved the allotment of 848,220 shares at 530 rupees each. Additionally, the company has approved the allotment of 650,000 warrants at the same price of 530 rupees each.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,586.70 | #1 3,80,702.50 | 33.18 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 51.86 | |
5,689.50 | 1,51,038.30 | 65.50 | 9,712.00 | 18.67 | 2,191 | 26.74 | 36.39 | |
1,499.40 | 1,21,107.70 | 22.45 | 28,409.50 | 7.12 | 5,291 | 9.88 | 38.89 | |
3,561.00 | 1,20,520.40 | 59.72 | 11,539.40 | 6.99 | 1,911 | 19.91 | 42.61 | |
1,253.10 | 1,04,580.10 | #1 18.40 | 33,741.20 | 16.73 | 5,725 | 1.26 | 46.51 | |
2,482.90 | 1,02,476.40 | 54.18 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 44.66 | |
975.00 | 98,107.80 | 21.07 | 23,511.00 | 18.55 | 4,615 | 2.60 | 50.50 | |
1,919.80 | 87,676.40 | 23.72 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.16 | |
5,433.00 | 64,959.70 | 28.53 | 13,458.30 | 3.70 | 2,216 | 21.39 | 61.31 | |
1,090.00 | 63,307.40 | 18.84 | 32,345.60 | 9.43 | 3,484 | -10.24 | 53.78 |
Forecast
Actual
Growth Rate
Revenue Growth
-7.05 %
Net Income Growth
-30.53 %
Cash Flow Change
-21.07 %
ROE
-32.90 %
ROCE
-28.49 %
EBITDA Margin (Avg.)
-11.97 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 137 | 181 | 194 | 226 | 279 | 295 | 297 |
| Fixed Assets | 24 | 34 | 90 | 93 | 93 | 92 | 87 |
| Current Assets | 96 | 104 | 96 | 123 | 163 | 160 | 165 |
| Capital Work in Progress | 15 | 41 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 98 | 107 | 104 | 133 | 186 | 203 | 210 |
| Total Liabilities | 137 | 181 | 194 | 226 | 279 | 295 | 297 |
| Current Liabilities | 49 | 57 | 53 | 73 | 83 | 85 | 78 |
| Non Current Liabilities | 1 | 4 | 8 | 7 | 3 | 3 | 6 |
| Total Equity | 87 | 121 | 133 | 147 | 193 | 207 | 213 |
| Reserve & Surplus | 75 | 109 | 121 | 134 | 178 | 194 | 200 |
| Share Capital | 12 | 12 | 12 | 12 | 13 | 13 | 13 |
Cash Flow
| Cash Flow | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -14 | -5 | 1 | -0 | 17 | -6 | -11 |
| Investing Activities | -15 | -37 | -18 | -9 | -6 | -6 | -1 |
| Operating Activities | 4 | 13 | 13 | 4 | -6 | -7 | -8 |
| Financing Activities | -4 | 19 | 6 | 4 | 29 | 6 | -2 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Apr 2025 | Jun 2025 |
| Promoter | 44.83 % | 44.83 % | 44.83 % | 43.60 % | 43.60 % | 43.60 % | 43.21 % | 43.21 % | 43.21 % | 43.21 % | 43.21 % | 43.21 % | 43.21 % | 42.99 % | 42.99 % | 42.99 % | 43.16 % | 40.46 % | 40.46 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.21 % | 0.11 % | 0.06 % | 0.06 % | 0.05 % | 0.12 % | 0.22 % | 0.00 % |
| DIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.13 % | 0.20 % | 0.20 % | 0.20 % | 0.00 % | 0.68 % | 0.99 % | 1.17 % | 1.17 % | 0.87 % | 0.69 % | 0.65 % | 0.64 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.06 % | 0.06 % | 0.05 % | 0.05 % |
| Public / Retail | 33.04 % | 32.97 % | 33.17 % | 34.23 % | 34.30 % | 35.02 % | 30.94 % | 31.35 % | 31.49 % | 31.43 % | 31.80 % | 31.90 % | 31.95 % | 31.57 % | 32.43 % | 32.96 % | 33.35 % | 31.58 % | 31.50 % |
| Others | 22.12 % | 22.20 % | 21.99 % | 22.18 % | 22.10 % | 21.38 % | 25.72 % | 25.24 % | 25.10 % | 25.16 % | 24.99 % | 24.00 % | 23.74 % | 24.21 % | 23.34 % | 23.08 % | 22.63 % | 27.04 % | 27.34 % |
| No of Share Holders | 4,965 | 5,263 | 5,595 | 9,140 | 9,300 | 9,107 | 8,418 | 8,273 | 8,233 | 8,272 | 9,419 | 10,252 | 10,639 | 10,652 | 10,792 | 10,576 | 10,435 | 10,592 | 10,808 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1 | 1 | 1 | 1 | 1 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.16 | 0.15 | 0.26 | 0.21 | 0.33 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 19 Sept 2021 |  Dividend | ₹ 1.00 /share | 16 Sept 2021 | 533.60 | 611.25 |
| 21 Sept 2022 | Dividend | ₹ 1.00 /share | 19 Sept 2022 | 636.50 | 1,140.80 |
| 21 Sept 2023 | Dividend | ₹ 1.00 /share | 20 Sept 2023 | 714.35 | 671.00 |
| 19 Sept 2024 | Dividend | ₹ 1.00 /share | 19 Sept 2024 | 515.65 | 462.40 |
| 26 Sept 2024 |  Annual General Meeting | NA | 26 Sept 2024 | 428.15 | 516.75 |
| 14 Nov 2024 |  Quarterly Result Announcement | NA | 14 Nov 2024 | 527.40 | 451.95 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 465.00 | 496.85 |
| 26 Mar 2025 |  Extraordinary General Meeting | NA | 26 Mar 2025 | 543.85 | 453.25 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 432.00 | 428.45 |
| 12 Aug 2025 | Quarterly Result Announcement | NA | 12 Aug 2025 | 378.60 | 359.95 |
| 19 Sept 2025 | Dividend | ₹ 1.00 /share | 19 Sept 2025 | 428.45 | 333.40 |
| 26 Sept 2025 | Annual General Meeting | NA | 26 Sept 2025 | 359.95 | 325.30 |
Announcements
Closure of Trading Window
19 hours ago
19 hours agoShareholder Meeting / Postal Ballot-Scrutinizers Report20 hours ago
20 hours agoShareholder Meeting / Postal Ballot-Outcome of AGM1 day ago
1 day agoRevised Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Sep 04, 2025
Sep 04, 2025Intimation Of Book Closure In Accordance With Regulation 42 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (Listing Regulations)Sep 04, 2025
Sep 04, 2025Reg. 34 (1) Annual Report.Sep 03, 2025
Sep 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 13, 2025
Aug 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 12, 2025
Aug 12, 2025Business Responsibility and Sustainability Reporting (BRSR)Aug 12, 2025
Aug 12, 2025Outcome Of The Board Meeting Held On August 12 2025Aug 12, 2025
Aug 12, 2025Board Meeting Intimation for For Consideration And Approval Of Unaudited Financial Results For The Quarter Ended On June 30 2025.Aug 07, 2025
Aug 07, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 29, 2025
Jul 29, 2025Closure of Trading WindowJun 30, 2025
Jun 30, 2025Announcement Under Regulation 30 (LODR)- Approval Of Abbreviated New Drug Application (ANDA)Jun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Jun 02, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Financial Results Year Ended On 31.03.2025May 30, 2025
May 30, 2025Board Meeting Intimation for Board Meeting Intimation As Per Regulation 29 Of The Securities And Exchange Board Of India (Listing Obligation And Disclosure Requirements) Regulation 2015 (Listing Regulations)May 22, 2025
May 22, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Apr 28, 2025
Apr 28, 2025Corrigendun To The Outcome Of The Board Meeting - April 24 2025Apr 25, 2025
Apr 25, 2025Board Meeting Outcome for Revised Outcome Of Board Meeting 24.04.2025Apr 25, 2025
Apr 25, 2025Board Meeting Outcome for Outcome Of Board Meeting - April 24 2025 (Allotment Of Securities)Apr 25, 2025
Apr 25, 2025Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Of Medicamen Biotech Limited In Accordance With Regulation 30 Of SEBI (LODR) Regulation 2015- Allotment Of Equity Shares & Fully Convertible WarrantsApr 24, 2025
Apr 24, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 23, 2025
Apr 23, 2025Disclosure Under Regulation 31(4) Of The Securities And Exchange Board Of India (Substantial Acquistion Of Shares And Takeovers) Regulation 2011 For The Financial Year Ended On March 31 2025Apr 08, 2025
Apr 08, 2025Announcement Under Regulation 30 (LODR) - UpdatesApr 08, 2025
Apr 08, 2025Announcment Under Regulation 30 (LODR)- UpdateApr 03, 2025
Apr 03, 2025Closure of Trading WindowMar 31, 2025
Mar 31, 2025Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 28, 2025
Mar 28, 2025Announcement Under Regulation 30 (LODR)- Expansion Into Regulated Markets And Long Term VisionMar 28, 2025
Mar 28, 2025Shareholder Meeting / Postal Ballot-Outcome of EGMMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations 2015Mar 22, 2025
Mar 22, 2025Corrigendum-Notice Of The Extra Ordinary General Meeting Scheduled To Be Held On Wednesday March 26 2025 At 12:00 Noon Through Video Conferencing ("VC")/ Other Audio-Visuals Means ("OAVM")Mar 20, 2025
Mar 20, 2025Announcement Under Regulation 30 (LODR) - UpdatesMar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 04, 2025
Mar 04, 2025Notice Of Extra Ordinary General Meeting - Wednesday March 26 2025Mar 03, 2025
Mar 03, 2025Announcement Under Regulation 30 (LODR) - MBL Has Been Awarded By Honble Health Minister Of EthiopiaFeb 27, 2025
Feb 27, 2025Announcement under Regulation 30 (LODR)-Issue of SecuritiesFeb 26, 2025
Feb 26, 2025Announcement Under Regulation 30 Of (LODR)- Clarification On Price MovementFeb 25, 2025
Feb 25, 2025Clarification sought from Medicamen Biotech LtdFeb 24, 2025
Feb 24, 2025Board Meeting Intimation for Issunce Of One Or More Instruments Including Equity Shares/Convertible Securities Either By Way Of Preferential Issue/ Right Issue/QIP Or Any Other Mode.Feb 21, 2025
Feb 21, 2025Announcement Under Regulation 30 (LODR)- Updates (Manufacturing And Supply Agreement)Feb 19, 2025
Feb 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 11, 2025
Feb 11, 2025Financial Results For The Quarter Ended On 31.12.2024Feb 11, 2025
Feb 11, 2025Integrated Filing (Financial)Feb 11, 2025
Feb 11, 2025Board Meeting Intimation for Consideration And Approval Of The Standalone And Consolidated Unaudited Financial Results Of The Company For The Quarter Ended On December 31 2024Feb 04, 2025
Feb 04, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 22, 2025
Jan 22, 2025Closure of Trading WindowDec 31, 2024
Dec 31, 2024Clarification On Price MovementDec 06, 2024
Dec 06, 2024Technical Indicators
RSI(14)
Neutral 23.35
ATR(14)
Volatile 13.74
STOCH(9,6)
Oversold 16.92
STOCH RSI(14)
Neutral 36.69
MACD(12,26)
Bearish -1.85
ADX(14)
Strong Trend 25.15
UO(9)
Bullish 23.82
ROC(12)
Downtrend And Accelerating -12.67
WillR(14)
Oversold -91.95
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
